AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05033015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mouth rinse
Description: To test a novel mouth rinse containing enzymes to prevent development of WSL with a control
Study NCT05620680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T cells
Description: patient was subjected to 0.5-2×10\^6 cells/kg of CD7 CAR- T
Study NCT06250400 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human histaglobulin
Description: once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;
Study NCT06250400 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;
Study NCT06250400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine 10 Mg
Description: orally, 10mg once a day for 4 weeks
Study NCT06250400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10 Mg
Description: orally, 10mg once a day for 4 weeks
Study NCT04661566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Education (Education)
Description: All participants will receive the basic educational component in the Mission Wellness app. This component will contain text and media (e.g., images, videos) to teach basic SRH topics. The exact information in this component will be determined by an assessment of baseline SRH knowledge at the start of the intervention.
Study NCT04695834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurolysis peroneal nerve
Description: The surgical approach for entrapment at the fibular head is usually through a curvilinear incision just distal to the fibular head. The subcutaneous tissue is bluntly dissected, and the common peroneal nerve is identified proximal to the peroneus longus muscle. The peroneal nerve is then released from the surrounding fibrous tissue and fascia. The nerve is decompressed distally as it dives under the peroneus longus muscle. The decompression at this site is essential. Certain authors state that an adequate decompression should extend beyond the bifurcation in the deep and superficial peroneal nerve and should involve cutting the intermuscular septa
Study NCT05364047 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0.5ml/person
Study NCT06150937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AEGIDA intervention arm
Description: The intervention arm has 4 sessions facilitated one-on-one by trained staff and lasting \~40 minutes. The first session focuses on establishing rapport, assessing HIV risk, and educating/training participants on HIV self-testing/PEP/PrEP. The second session on peer education/training, barriers to and facilitators of testing, and supporting peers in receiving reactive and/or indeterminate HIV test results, as well as self-care. The third session on stigma and discrimination and techniques to cope with and resist stigma. The final session is a culminating one focused on reviewing key skills and health promotion planning conducted in first three sessions. The intervention arm applies anti-intersectional stigma, empowerment, and harm reduction approaches. All participants will receive/have access to HIV self-test kits every three months.
Study NCT06150937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AEGIDA control arm
Description: The control arm has 4 sessions via one-on-one facilitation by a trained facilitator and lasting \~40 minutes. It includes basic information on self-screening for common adverse health conditions among women in Kazakhstan, including STIs and HIV, as well as information on testing and risk reduction. All participants will receive/have access to HIV self-test kits every three months.
Study NCT04695834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maximal physiotherapy
Description: Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule
Study NCT05389137 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inavtivated Quadrivalent Influenza Virus Split Vaccine
Description: Prevent influenza caused by H1N1, H3N2, B (V), B (Y) strain virus infection.
Study NCT04661566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Videos (Narratives)
Description: The narrative video component is a motivation-based component that includes stories of individuals engaging in positive and negative SRH behaviors that lead to either positive or negative outcomes, respectively, in a video format.
Study NCT04661566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Building Videos (Skills)
Description: The skills-building videos component is a component rooted in behavioral skills that involves the provision of information on how to perform or engage positive SRH behaviors (e.g., correctly using a condom, what to expect when having a Pap smear) via instructional videos.
Study NCT04661566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Scenarios (Scenarios)
Description: The interactive scenarios are a behavioral skills-building component that walks through conversations surrounding SRH with select individuals (e.g., partner, healthcare provider), providing suggestions on how to have these conversations and why these conversations are important to have.
Study NCT04744480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The combined topical anesthesia induction group
Description: The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
Study NCT00006154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indinavir sulfate
Description: 400 mg tablets equaling 1600 mg daily
Study NCT00006154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg liquid capsules equaling 400 mg daily
Study NCT00006154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir sulfate
Description: 300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
Study NCT00006154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir sulfate
Description: 300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
Study NCT00006154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 200 mg capsules equaling 600 mg daily
Study NCT00006154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 30-40 mg capsules equaling 60 or 80 mg daily
Study NCT00006154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine
Description: 250-400 mg E.coated tablets equaling 250 or 400 mg daily
Study NCT00006154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Didanosine
Description: 250-400 mg E.coated tablets equaling 250 or 400 mg daily
Study NCT00006154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
Study NCT00006154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldesleukin
Description: Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
Study NCT04661566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Life Planning Tool (Future)
Description: The future life planning tool is a motivation-based component contains a series of questions to help users plan future goals to put current decision making related to SRH into perspective and provide suggestions on how to stay healthy now to be able to achieve those goals later.
Study NCT05650580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR115
Description: TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
Study NCT04661566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Epidemiological Risk Scenario (Risk)
Description: The risk component is an information- and motivation-based component with tailored epidemiological risk information about relative risk of contracting a specific STI and/or having an unintended pregnancy. Relative risk information will be determined by adjusting variables within the component (e.g., number of partners within the last month, percent of time using condoms).
Study NCT04433845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Open-label
Study NCT05911854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-waved Locked System Laser
Description: The M6 therapy laser is a robotized multi-target device designed to treat patients suffering pathologies affecting a wide area, and to perform automatic applications.
Study NCT05911854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Compression therapy
Description: The BioCryo Cold Compression System is a cold therapy pneumatic compression device that safely administers sequential, gradient pneumatic compression and CryoTherapy combined.
Study NCT05911854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complete decongestive therapy
Description: Complete decongestive therapy consists of:~* Meticulous skin care with the use of emollients~* Using short stretch bandages or continuous wearing of a pressure garment~* Manual lymphatic drainage therapy~* Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)
Study NCT05911854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complete decongestive therapy
Description: Complete decongestive therapy consists of:~* Meticulous skin care with the use of emollients~* Using short stretch bandages or continuous wearing of a pressure garment~* Manual lymphatic drainage therapy~* Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)
Study NCT06615531 — intervention group
Intervention type: BEHAVIORAL
Intervention: Advanced multi-component meditation practice
Description: The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
Study NCT05850689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily
Study NCT05850689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally, once daily
Study NCT05462366 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: Collect breast-milk and feces from mother-infant-pairs.
Study NCT05577429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-moderate intensity exercise under normoxia
Description: The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 20.9%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
Study NCT05577429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-moderate intensity exercise under moderate hypoxia
Description: The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 16.5%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
Study NCT05577429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-moderate intensity exercise under high hypoxia
Description: The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 14.8%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
Study NCT06534515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomatis auditory stimulation
Description: Traditional Tomatis Method Protocol
Study NCT05403489 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
Study NCT05403489 — intervention group
Intervention type: PROCEDURE
Intervention: endotracheal aspirate culture
Description: In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
Study NCT04781153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: Periodontal treatment (scaling and rootplaning) with adjunctive chlorhexidine use
Study NCT05014165 — intervention group
Intervention type: OTHER
Intervention: Cord blood Sample Collection
Description: Obtain banked cord blood samples from consecutive childhood leukemia patients
Study NCT05014165 — intervention group
Intervention type: OTHER
Intervention: Case identification and recruitment
Description: Cases meeting eligibility and who have given consent through APEC14B1 for future contact for non-therapeutic studies
Study NCT05014165 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: The family will be given an option to complete questionnaire on paper, online, or over the telephone.
Study NCT06068686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG
Description: vildagliptin plus their metformin.
Study NCT06068686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 3 Mg Oral Tablet
Description: glimepiride plus their metformin
Study NCT05057234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FoundationOne liquid CDx
Description: FoundationOne liquid CDx testing
Study NCT05057234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Description: Quality of life questionnaire - EQ5D
Study NCT05363852 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard set of visual word and picture stimuli
Description: Set ot 145 stimuli: 115 words (three sets of 35 words with positive, neutral, and negative content) and 30 pictures (two sets of 15 photos with positive and negative content).
Study NCT05403723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 50 MG/1 ML Intravenous Solution
Description: Durvalumab (1500 mg durvalumab via IV infusion) in combination with platinum doublet chemotherapy will be administered to patients once every 3 weeks for up to 4 cycles plus SBRT (platinum resistant group) or without SBRT (platinum sensitive group). Each 3-week of chemoimmunotherapy interval is considered a cycle. Patients with platinum sensitive disease will receive the combination of durvalumab and chemotherapy (total of four cycles) while those with platinum resistant SCLC will receive SBRT and continue to receive up to two additional cycles of treatment with durvalumab along with platinum/etoposide (not to exceed a total of four6 cycles of chemoimmunotherapy including 2 cycles obtained prior to SBRT). Following completion of 4-6 cycles of combination therapy, patients in both groups will continue with maintenance durvalumab (1500 mg) in q4w cycles until disease progression.
Study NCT05403723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Injection
Description: A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
Study NCT05403723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
Study NCT05403723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
Study NCT05403723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Patients will receive palliative radiation to the primary tumor site up to 30 Gy for 1 week given as 5 daily fractions of 6 Gy each or 27 Gy as 3 fractions of 9 Gy administered every other day.
Study NCT04596930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser ablation thermal therapy
Description: The Visualase Thermal Therapy System is used to necrotize or coagulate soft tissue through interstitial irradiation under MRI guidance
Study NCT05430282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only vestibular rehabilitation
Description: Vestibular adaptation exercises, static and dynamic balance exercises, proprioceptive and conditioning exercises.
Study NCT05430282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical exercises in addition to vestibular rehabilitation
Description: Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.
Study NCT05430282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical exercises in addition to vestibular rehabilitation
Description: Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.
Study NCT06264440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122
Description: Administered as specified in the treatment arm.
Study NCT05573373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parimparib
Description: The dosage and protocol of the drug were carried out according to the description.
Study NCT06264440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Administered as specified in the treatment arm.
Study NCT05499741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forehead Temperature-Regulating Therapy
Description: A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.
Study NCT05573373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: The dosage and protocol of the drug were carried out according to the description.
Study NCT05573373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Therapy Agent
Description: The dosage and protocol of the drug were carried out according to the description.
Study NCT05409014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT
Description: The phase 1 of the protocol was awareness-raising, the athlete receives guidance from a physical therapist and learns the location of the PFM and the ability to contract them in isolation. The phase 2 is stabilization, consisting of 15 stabilization exercises, which are performed through pelvic floor contractions for 10 seconds and with the same relaxation time, repeating each group 10 times. The phase 3 is strength, the same exercises as the second phase are performed using 2 kg weights at the end of each leg and/or arm. There are eight groups of exercises and with changes in the time of slow contraction and relaxation. The phase 4 is power, in power exercises the training loads are increased and the sequence of movements is also increased. The phase 5 is to complement the power, this phase was the continuation of the previous one in the sense of potentiation of the results where ballistic movements, speed and impact fundamentally predominate.
Study NCT04223661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide Pill
Description: Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.